Hansen Pharma’s 50%+ Profit Surge Fuels Mid-Cap Innovation-Drug Rally in China
HANSEN Pharma surges as China’s innovation‑drug boom fuels a 50%+ earnings jump and a 2‑day limit‑up streak, spotlighting strong growth prospects.
4 minutes to read
HANSEN
HANSEN Pharmaceutical Soars to Limit‑Up on April 28, 2026 Amid Shenzhen’s Market Dip
HANSEN 002412’s limit‑up on April 28 reflects its robust, diversified drug portfolio and sector resilience, offering attractive upside amid a correcting market.
3 minutes to read